These drugs act by means of hepatic activation: the active metabolite selectively and irreversibly inhibits platelet aggregation induced by adenosine adenosindiphosphate ADP, preventing thus bonding mechanism to the platelet receptor.
Ejercen su efecto a través de una activación hepática, el metabolito activo inhibe selectiva e irreversiblemente la agregación plaquetaria inducida por la adenosindifosfato ADP, impidiendo su unión al receptor plaquetario.